2 thoughts on “Covid Vaccine: Shrunken Placenta With White Dots

  1. What is wrong with this picture ? :

    This Practice Advisory was developed by the American College of Obstetricians and Gynecologists’ Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group in collaboration with Laura E. Riley, MD; Richard Beigi, MD; Denise J. Jamieson, MD, MPH; Brenna L. Hughes, MD, MSc; Geeta Swamy, MD; Linda O’Neal Eckert, MD; Mark Turrentine, MD; and Sarah Carroll, MPH.

    Summary of Updates
    This Practice Advisory provides an overview of the currently available COVID-19 vaccines and guidance for their use in pregnant, recently pregnant, lactating, and nonpregnant individuals aged 12 years and older. For guidance and recommendations for the use of these vaccines in individuals aged 11 years or younger, please visit the website of the American Academy of Pediatrics. For additional information regarding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and treatment, see ACOG’s Frequently Asked Questions.

    This Practice Advisory has been updated to include the following:

    Recommendation for the use of bivalent boosters for all individuals age 6 months and older.
    Key Recommendations
    The American College of Obstetricians and Gynecologists (ACOG) recommends that all eligible persons aged 6 months and older, including pregnant and lactating individuals, receive a COVID-19 vaccine or vaccine series.
    Messenger RNA (mRNA) and Novavax COVID-19 vaccines are preferred over the Johnson & Johnson/Janssen (J&J/Janssen) COVID-19 vaccine for most individuals, including pregnant and lactating individuals, for primary series.
    mRNA COVID-19 vaccines are preferred over the J&J/Janssen COVID-19 vaccine for primary additional doses (for immunocompromised persons) and for booster vaccination.
    ACOG recommends that all people, including pregnant people receive a bivalent mRNA COVID-19 vaccine booster dose following the completion of their last COVID-19 primary vaccine dose or monovalent booster.
    Bivalent mRNA COVID-19 vaccines are the default for booster vaccination. However, Novavax’s monovalent COVID-19 vaccine is allowable for use as a booster (not primary vaccination) for individuals aged 18 years and older when they have not yet received any booster dose and:
    are unable to get a bivalent mRNA COVID-19 vaccine, or
    are unwilling to get a bivalent mRNA COVID-19 vaccine
    Bivalent mRNA COVID-19 vaccines are only authorized for use as boosters. They are not authorized for use as primary doses at this time. Individuals must complete their primary monovalent COVID-19 vaccine series before receiving a bivalent mRNA COVID-19 booster.
    Vaccination may occur in any trimester, and emphasis should be on vaccine receipt as soon as possible to maximize maternal and fetal health. This recommendation applies to both primary series and booster vaccination.
    For patients who do not receive any COVID-19 vaccine, the discussion should be documented in the patient’s medical record. During subsequent office visits, obstetrician–gynecologists should address ongoing questions and concerns and offer vaccination again.
    Obstetrician–gynecologists and other women’s health care practitioners should lead by example by being vaccinated and encouraging eligible patients to be vaccinated as well.
    COVID-19 vaccines may be administered simultaneously with other vaccines. This includes vaccines routinely administered during pregnancy, such as influenza and Tdap.
    Moderately to severely immunocompromised individuals (i.e., people who have undergone solid organ transplantation or have been diagnosed with conditions that are considered to have an equivalent level of immunocompromise) should receive an additional dose (i.e., an additional primary dose) of COVID-19 vaccine after their initial vaccine or vaccine series. The additional dose should be administered four weeks after the completion of the initial COVID-19 vaccine or vaccine series. For mRNA vaccines, this means immunocompromised individuals need a 3-dose primary series. For J&J/Janssen vaccine, immunocompromised individuals need a 2-dose primary series with the second dose being an mRNA vaccine.

    1. Fred, my understanding is that there were no studies on pregnant women receiving the vaccine.

      The ACOG ought to be liable for what they recommended– in a big way. Indeed, if we truly had justice, there would be much more than mere tort liability.

Comments are closed.